Frontier Medicines is a precision-medicine company based in South San Francisco and Boston. It focuses on discovering and developing therapies targeting disease-causing proteins that have historically been considered undruggable. The company's work centres on cancer therapeutics, with a lead programme developing a KRAS G12C inhibitor designed to block both the activated and inactive forms of the protein in genetically defined patient populations.
Technologically, Frontier Medicines combines chemoproteomics and covalent drug discovery with machine learning. These capabilities underpin its proprietary platform, which the company says has identified thousands of druggability opportunities across the proteome - a resource it calls the Druggability Atlas.
For engineers and data scientists, the intersection of high-throughput proteomics data, covalent chemistry and ML-driven target identification presents a distinctive technical environment. The company operates at the boundary of wet-lab science and computational methods, applying modern machine-learning techniques to biological datasets at scale.
